Jack (John) McGinty, PhD is a research scientist at 2seventy Bio, a biotech company making cutting-edge immunotherapies for the treatment of cancer. His current work focuses on the development of CAR T cell therapy. In this process patient T cells are isolated, genetically reprogrammed, and injected into the body where they detect and kill cancer cells. Dr. McGinty holds a PhD in Immunology from the University of Washington, where he studied host immune responses to parasite infection, as well as a B.S. in Microbiology from Ohio University.